1. Medtech Insight
  2. >>Geography
  3. >>Europe

Despite Setbacks, Emphysema Devices Find Funding

Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.

For innovators and investors, the path to developing a minimally invasive device for treating emphysema has been filled with both opportunity and obstacles. The market opportunity is vast. The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise and will become the third leading cause of death by 2030. In the US, where nearly five million people are diagnosed with emphysema, the direct and indirect costs of COPD reached almost $50 billion in 2010, and the prevalence of patients with severe and very severe emphysema in key markets worldwide is estimated at more than 1.5 million, according to Uptake Medical Corp., a competitor in this space. (See Exhibit 1.)

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Under Pressure: How To Safeguard The EU Responsible Person

 
• By Amanda Maxwell

The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.

Number of Persons Responsible For Regulatory Compliance Grows Nearly 10%

 
• By Amanda Maxwell

The EU’s Medical Device and IVD Regulations require every manufacturer and authorized representative to have a PRRC. As compliance becomes mandatory for increasing numbers of manufacturers, figures are soaring and this role is becoming both increasingly distinctive and more complex.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

UK MHRA Deepens AI Regulatory Expertise As Airlock Moves Into Phase 2

 
• By Ashley Yeo

The first-of-its-kind sandbox for insights on how to regulate artificial intelligence in healthcare has accepted seven more AI innovators onto its learning program.

More from Geography

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.

US FDA Warning Letters - Sept.-Oct. 2025

The US FDA issued eight warning letters in September and October, with ultrasound, surgical and mobile apps among the affected product types.